PRELUDE CAPITAL MANAGEMENT, LLC - ONCOGENEX PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
PRELUDE CAPITAL MANAGEMENT, LLC ownership history of ONCOGENEX PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2017$2,000
-77.8%
6,600
-68.7%
0.00%
-100.0%
Q1 2017$9,000
+125.0%
21,100
+145.3%
0.00%
Q4 2016$4,000
+33.3%
8,600
+30.3%
0.00%
Q3 2016$3,000
-40.0%
6,600
+43.5%
0.00%
-100.0%
Q2 2016$5,000
-54.5%
4,600
-0.7%
0.00%
-50.0%
Q4 2014$11,000
-8.3%
4,6330.0%0.00%0.0%
Q3 2014$12,000
-29.4%
4,6330.0%0.00%0.0%
Q2 2014$17,000
-79.0%
4,633
-32.9%
0.00%
-81.8%
Q1 2014$81,000
+376.5%
6,900
+246.4%
0.01%
+266.7%
Q4 2013$17,000
-5.6%
1,9920.0%0.00%0.0%
Q3 2013$18,000
-63.3%
1,992
-60.2%
0.00%
-72.7%
Q2 2013$49,0005,0000.01%
Other shareholders
ONCOGENEX PHARMACEUTICALS IN shareholders Q3 2017
NameSharesValueWeighting ↓
Steamboat Capital Partners, LLC 817,521$414,0000.37%
Abingworth LLP 396,104$195,0000.19%
BOOTHBAY FUND MANAGEMENT, LLC 60,638$31,0000.01%
EAGLE GLOBAL ADVISORS LLC 128,520$65,0000.00%
PANAGORA ASSET MANAGEMENT INC 949,438$481,0000.00%
Renaissance Technologies 908,100$460,0000.00%
PRICE T ROWE ASSOCIATES INC /MD/ 46,100$23,0000.00%
DEUTSCHE BANK AG\ 5$00.00%
CITIGROUP INC 10,376$5,0000.00%
GOLDMAN SACHS GROUP INC 20,037$10,0000.00%
View complete list of ONCOGENEX PHARMACEUTICALS IN shareholders